Relatório Trimestral
![Carmignac](https://carmignac.imgix.net/uploads/article/0001/18/%5BMain-Media%5D-CED.jpg?auto=format%2Ccompress)
Carmignac Portfolio Emerging Discovery: Letter from the Fund Managers
Carmignac Portfolio Emerging Discovery (A EUR ACC share class, ISIN LU03360838101) was up +3.91% during the third quarter versus -1,20% for its reference indicator2, making up for around half of the under-performance accumulated by the fund since the beginning of the year, which, as a reminder, was largely due to its Russian exposure. Since the beginning of the year, the fund retuned -18.29% versus -12.65% for its composite reference indicator.
Performance explanation
The past quarter’s strong performance was mainly due to India. Two things played in our favor. Firstly, the fund had a significant overweight position in India, with an average exposure of 24% over the quarter to be compared with 18% for its reference indicator. And secondly, we were rewarded by our stock picking. Our Indian portfolio was up 31.9% over the quarter vs 17.6% for our reference indicator1 .
More specifically, our consumer names Sapphire Foods and Varun Beverages were the top two contributors to the fund during the quarter. While most Asian countries are seeing their economic activity collapse as a consequence of weakening exports, India, on the other hand, is experiencing an uptick in domestic credit and investments. This is supporting domestic demand and consumption. Our Indian healthcare names also performed very well, especially Max Healthcare which was added to the fund during the summer. We bought a very large position in August when the company raised Equity.
Max Healthcare is the second largest hospital chain in India, with 17 facilities and a current capacity of 3,400 beds which is rising rapidly. The company acquired land with the intention to add 1,000 beds in Greenfield hospitals in highly attractive regions where penetration is low. Max Healthcare is a profitable business despite a very aggressive growth plan unveiled in the past three years that allowed its EBITDA to grow more than 50% per year. Max Healthcare has been displaying one of the best standards of clinical excellence and patient care among its peers, which is of prime importance in a country where there is little availability of quality healthcare. Note that Max Healthcare accounts for 8.2% of the fund, an illustration of our willingness to reduce the number of positions and have a more concentrated portfolio that focuses on our strongest convictions. Our top 10 positions account for 48% of the fund, the highest number in years.
During the quarter, we also added Salik, a toll road operator in Dubai. The macro backdrop in the UAE (United Arab Emirates) looks very positive, thanks to the obvious support of higher oil prices, but also to the Government’s successful initiatives to attract business. Salik’s traffic is driven by the demographics of the country, which is dynamic thanks to Dubai’s popularity as a tourist and business hub. The Government put in place the Golden Visa program for retired people and remote workers, it decided to host more than 400 global events per year by 2025 to attract more visitors and launched the 2040 Urban Master Plan to develop and invest in five main urban centers, three of which will be connected to existing toll gates. This plan is expected to increase the population of Dubai to 5.8mn by 2040 from the current 3.4mn. Being a monopolistic State-Owned enterprise, we believe that Salik’s business does not have a material regulatory risk and the valuation exercise is made easier by the automatic inflation adjustment to toll prices. We decided to buy in the IPO of the company because our analysis indicated an attractive Equity risk premium to sovereign yields, which we believe does not make sense with regards to the risk profile of the business.
Outlook for the next months
Taking into account the much higher long term real yields in the US curve, we have decided to have a conservative approach, which is why we have put in place a hedging strategy on our Indian portfolio on both the currency and the Equity market for around 10% of the fund.
While we clearly like the names that we own in India, we acknowledge that Indian Equities have been holding up very well in relative terms, which brings the risk of a sudden draw-down which would affect the fund. We would like to take the opportunity to remind our investors that our hedging strategies are limited in both magnitude and time. They are used in exceptional circumstances for a limited amount of time when we believe that it is in the interest of the fund to use derivatives which are liquid and cost-free rather than move the portfolio directly. We have also reduced the risk of the fund by trimming some of our cyclical positions, especially in Korea and Taiwan, in the semi-conductor space for instance, which are deep cyclical names.
However, as we head into the 4th quarter, we are seeing some signs of capitulation in the market, usually an opportunity to re-expose the fund, which is why we are becoming more and more confident for 2023 and we believe our next moves will be bullish ones.
Sources: Carmignac, Bloomberg, 30/09/2022
[1] Performance of the A EUR acc share class ISIN code: LU0336083810. Past performance is not necessarily indicative of future performance. The return may increase or decrease as a result of currency fluctuations. Performances are net of fees (excluding possible entrance fees charged by the distributor). From 01/01/2013 the equity index reference indicators are calculated net dividends reinvested.
[2] 50% MSCI EM SmallCap (EUR) + 50% MSCI EM MidCap (EUR) (Reinvested net dividends rebalanced quarterly).
Bloomberg, 30/09/2022
Carmignac Portfolio Emerging Discovery A EUR Acc
Horizonte de investimento mínimo recomendado
Risco mais baixo Risco mais elevado
. .
Ações: O Fundo pode ser afetado por variações nos preços das ações, numa escala que depende de fatores externos, volumes de negociação de ações ou capitalização bolsista.
Países emergentes: As condições de funcionamento e de supervisão dos mercados "emergentes" podem desviar-se das normas em vigor nas principais praças mundiais e ter implicações nas cotações dos instrumentos cotados nos quais o Fundo pode investir.
Cambial: O risco cambial está associado à exposição a umamoeda que não seja a moeda de avaliação do Fundo, através de investimento direto ou do recurso a instrumentos financeiros a prazo.
Liquidez: As distorções temporárias do mercado podem influenciar as condições de avaliação em que o Fundo pode ser levado a liquidar, iniciar ou modificar as suas posições.
Este fundo não possui capital garantido.
Carmignac Portfolio Emerging Discovery A EUR Acc
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
2024 (YTD) ? Desde o início do ano até à data |
|
---|---|---|---|---|---|---|---|---|---|---|---|
Carmignac Portfolio Emerging Discovery A EUR Acc | +13.12 % | +2.99 % | +3.76 % | +17.91 % | -8.90 % | +9.98 % | -0.16 % | +25.55 % | -22.39 % | +12.66 % | +17.40 % |
Indicador de Referência | +12.98 % | +0.19 % | +6.67 % | +18.14 % | -11.64 % | +14.39 % | +5.35 % | +21.27 % | -11.67 % | +14.93 % | +7.52 % |
Deslocar para a direita para ver a tabela completa
3 anos | 5 anos | 10 anos | |
---|---|---|---|
Carmignac Portfolio Emerging Discovery A EUR Acc | +2.37 % | +4.59 % | +5.06 % |
Indicador de Referência | +4.20 % | +7.91 % | +6.03 % |
Deslocar para a direita para ver a tabela completa
Fonte: Carmignac em 31/07/2024
Custos de entrada : | 4,00% do montante que paga ao entrar neste investimento. Este é o valor máximo que lhe será cobrado. Carmignac Gestion não cobra custos de entrada. A pessoa que lhe vender o produto irá informá-lo do custo efetivo. |
Custos de saída : | Não cobramos uma comissão de saída para este produto. |
Comissões de gestão e outros custos administrativos ou operacionais : | 2,30% O impacto dos custos que suportamos anualmente pela gestão dos seus investimentos e outras comissões administrativas. Esta é uma estimativa baseada nos custos efetivos ao longo do último ano. |
Comissões de rendimento : | 20,00% quando a classe de ações supera o indicador de referência durante o período de desempenho. Será pago também no caso de a classe de ações ter superado o indicador de referência, mas teve um desempenho negativo. O baixo desempenho é recuperado por 5 anos. O valor real varia dependendo do desempenho do seu investimento. A estimativa de custo agregado acima inclui a média dos últimos 5 anos, ou desde a criação do produto se for inferior a 5 anos. |
Custos de transação : | 0,52% O impacto dos custos inerentes às nossas operações de compra e de venda de investimentos subjacentes ao produto. |